NCT02073929View on ClinicalTrials.gov

LIPT - Liraglutide in Polycystic Ovary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Polycystic Ovary SyndromeCardiovascular Disease
Interventions
DRUG

Liraglutide for 26 weeks

GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks

DRUG

placebo

Placebo s.c. daily for 26 weeks

Trial Locations (3)

2730

Dept. of Medicine and Dept. of Gyn-Obs, Herlev Hospital, Herlev

Herlev Hospital, Dept of Gynecology, Herlev

DK-2730

Dept. of Medicine and Dept. of Obstetrics and Gynaecology, Herlev Hospital, Herlev

All Listed Sponsors
lead

Jens Faber

OTHER

NCT02073929 - LIPT - Liraglutide in Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter